KATELYN DUPRE: Open Payments
NPI 1609558055 · NEW ROADS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,277 in 59 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $975 · 2025 $1,277
Food & beverage: $1,277
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $316 |
| Axsome Therapeutics, Inc. | 7 | $242 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $204 |
| ABBVIE INC. | 11 | $179 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| Lundbeck LLC | 4 | $70 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| Corium, LLC | 2 | $38 |
| Contego Medical, Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: Auvelity, CAPLYTA, ARISTADA, VRAYLAR, REXULTI, LYBALVI, FANAPT, Azstarys.
Industry payments across LA — which companies pay providers there.
